• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Scribe Therapeutics Eyes Mid-2026 Debut for STX-1150

    BUSINESSWIRE

    Scribe Therapeutics Presents at 44th JPM Healthcare Conference

    BUSINESSWIRE

    Scribe Eyes Clinic As CRISPR Candidates Lower Lipids In Animals

    FIERCE BIOTECH

    Scribe Showcases Lp(a)-Lowering Therapy & AI CRISPR Platform

    PHARMAWEB

    Scribe Therapeutics Reports Positive Preclinical Data on Novel CR

    BUSINESSWIRE

    Scribe to Present Crispr Based Data for Duchenne Muscular Dystrophy

    BUSINESSWIRE

    Scribe, Prevail to Present In Vivo AAV Tech at ASGCT

    BUSINESSWIRE

    Scribe Therapeutics to Present Preclinical Data on CRISPR at 2025

    BUSINESSWIRE

    Scribe Therapeutics to Participate in Upcoming Conferences

    BUSINESSWIRE

    Scribe Therapeutics Hits Milestone in Sanofi Collaboration

    BUSINESSWIRE

    Scribe Therapeutics to Present at J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    Gene editor Scribe slims down workforce as it readies for clinic

    FIERCE BIOTECH

    Scribe Validates CRISPR Tech for Cardiometabolic Disease at AHA

    BUSINESSWIRE

    Scribe Therapeutics to Present Preclinical CRISPR Data at AHA

    BUSINESSWIRE

    Scribe In Vivo Gene Editing, Epigenetic Editing At ASGCT

    BUSINESSWIRE

    Scribe At ASGCT On CRISPR Genome, Epigenome Editing

    BUSINESSWIRE

    Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

    BUSINESSWIRE

    Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

    BUSINESSWIRE

    Scribe Therapeutics Presents Data on its X-Editing Technologies at ASGCT

    BUSINESSWIRE

    Scribe`s CRISPR tech Prevails with new $1.5B Lilly biobucks deal

    FIERCE BIOTECH

    Scribe Therapeutics Announces Oral Presentation at 2023 (ASGCT) Annual Meeting

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.